NSRX — Nasus Pharma Ltd
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 2029039 ·
Last close
$3.63
Market Cap
$42.52M
52W High
$9.50
52W Low
$1.98
ADV30
17,741
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 12,449,000 | 7,818,000 | 1,453,000 |
| Dec 2025 | — | — | — | — | 5,004,000 | 1,237,000 | 2,236,000 |
| Jun 2025 | — | — | — | — | 639,000 | 203,000 | 4,953,000 |
| Dec 2024 | — | — | — | — | 717,000 | 284,000 | 3,929,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-18,520,000
Inventory
—
Receivables
—
ST Investments
$3,049,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -4,904,000 | -5,856,000 | 5,004,000 | 2,236,000 | 2,768,000 | -4,918,000 |
| Dec 2024 | 0 | -1,078,000 | -1,532,000 | 717,000 | 3,929,000 | -3,212,000 | -665,000 |
| Dec 2023 | 0 | -1,147,000 | -1,051,000 | 444,000 | 4,241,000 | -3,797,000 | -1,029,000 |
| Dec 2022 | 0 | -2,042,000 | -1,711,000 | 417,000 | 3,202,000 | -2,785,000 | -1,211,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GRCE | Grace Therapeutics, Inc. | $42.91M | $2.04 | — |
| SCYX | SCYNEXIS INC | $41.99M | $4.22 | — |
| MTNB | Matinas BioPharma Holdings, Inc. | $41.58M | $2.83 | — |
| CPHI | CHINA PHARMA HOLDINGS, INC. | $41.30M | $0.96 | — |
| VERU | VERU INC. | $41.26M | $2.42 | — |
News headlines (Yahoo Finance, 1h cache)
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
2026-09-29 12:00 · Yahoo
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
2026-09-14 12:00 · Yahoo
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 11:30 · Yahoo
NSRX: First Half 2026 Financial Results
2026-08-21 11:00 · Yahoo
Nasus Pharma Announces Transition of Chief Financial Officer
2026-08-19 11:00 · Yahoo
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
2026-08-17 12:14 · Yahoo
Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth
2026-07-28 11:30 · Yahoo
Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis
2026-06-01 12:00 · Yahoo
Nasus Pharma to Participate in Upcoming Investor Conferences
2026-05-01 13:14 · Yahoo
NSRX: Initiating Coverage – Sniffing Out a Better Solution
2026-05-22 07:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.